Imagify™ (perflubutane polymer microspheres) injectible suspension was developed to enable ultrasound to become a viable alternative to nuclear stress testing, matching its accuracy but with a lower cost, better convenience and radiation-free profile.
Nuclear Stress |
Stress Ultrasound |
|
|
|
|
|
|
|
|
Based on Acusphere’s two completed Phase 3 studies, RAMP-1 and RAMP-2, Imagify enhanced cardiac stress ultrasound yields information clinically equivalent to that of the nuclear stress test. Once approved by the European EMA, Imagify stands to become the first ultrasound contrast agent for myocardial perfusion assessment.